Time for recognition of lay counsellors
Accessed November 2017
World's largest Science, Technology & Medicine Open Access book publisher
Chapter 7 from the book People's Movements in the 21st Century - Risks, Challenges and Benefits
Trials (2017) 18:152, DOI 10.1186/s13063-017-1881-z
Guidelines
June 2017
HIV strategic information for impact
Treating children infected with intestinal worms is one of the simplest and most cost–effective ways to improve their health.
The recommendations are intended for a wide audience, including policy-makers and their expert advisers as well as technical and programme staff at government institution...s and organizations involved in the design, implementation and expansion of programmes to control soil-transmitted helminth infections.
more
Recommendations, resources and references
A publication of the Southern African HIV Clinicians Society
HIV Treatment
Policy Brief
July 2017
Review
www.co-hivandaids.com
Volume 12 Number 4 July 2017
Technical Update
HIV Treatment
July 2017
CORE Group has developed a module to improve preparedness for and response of communities in countries at risk of a cholera epidemic. The module consists of four lesson plans with accompanying flipcharts, intended to be delivered through community health workers. The lessons target mothers and careg...ivers of children under age five, a group that is at particular risk of death if infected. The module shares information about symptoms and risks; what families can do to prevent infection; how, when, and where to seek care; and what actions to take in the aftermath of an outbreak.
more
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more